The early-stage biopharma announced more details about a share offering to raise much-needed capital.
New technology could boost solar efficiency and drive down costs in the next few years. Future materials could even generate electricity at night.
The biosimilar developer received some good news from a regulator.
The two propane distributors offer investors high yields of over 9%, but they need to come to grips with the risks climate change poses to their businesses.
Four separate updates are sending shares higher today. Perhaps the biggest contributor: buyout rumors.
The food ingredient manufacturer announced underwhelming preliminary second-quarter 2018 results.
The industry used to be home to some of the best high-yield stocks on the market, but many dividends have yet to recover from the breakup of a huge cartel in 2013.
The company was already leading efforts to relieve the Permian Basin's pipeline bottleneck. Then it announced a joint venture with ExxonMobil.
Diesel is out and electric is in at Goldcorp's Borden project in Canada. The all-electric strategy could enable huge cost savings if applied across the portfolio.
Investors are bidding up shares as the first drug candidates using the gene-editing technology inch closer to the clinic.
The $15 billion company has continued to grow quarterly revenue at a 40% clip.
Slowing growth has concerned Wall Street, but long-term investors have few reasons to worry.
The DNA sequencing leader announced upgrades to some of its core offerings.
Investors began paying closer attention to the results from two studies suggesting a link between certain gene-editing tools and cancer.
A low-cost cardboard manufacturer down on its luck, the newest fertilizer stock, and an energy leader are all worth a closer look this month.
Investors know the conglomerate will split into three by June 2019. Is a blanket investment approach best, or should investors be more strategic?
A well-managed infrastructure stock yielding 5%, a top supplier to oil drillers, and a leading global tire manufacturer are down as much as 28% in 2018. Are they buys?
Strong growth in consumables revenue is keeping Wall Street happy as it awaits the continued rollout of the latest gene-sequencing machine.
SolarEdge Technologies grew first-quarter 2018 revenue 82% from the prior year, but an onslaught of bad news has dimmed investors' excitement.
The genetic testing leader is growing at a healthy clip, but still burning through piles of cash.